Clinical Trial Update: Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 clinical trial evaluating atrasentan for patients with progressive or recurrent malignant glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Central Nervous System Tumors
• Malignant Glioma

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED